Neuroscientific Biopharmaceuticals (ASX:NSB) share price leaps 11% on study update

This comes after the release of an announcement. Let's take a further look.

| More on:
jump in asx share price represented by man leaping up from one wooden pillar to the next

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price has jumped into the green during afternoon trade on Friday.

Neuroscientific shares are on the move as the company released an announcement on its EmtinB label.

Let's investigate further.

What did Neuroscientific announce?

After recommencing trade after Thursday's trading pause, Neuroscientific provided additional colour on its announcement from 19 August.

Recall that Neuro' announced on Thursday that its EmtinB label indicated "strong therapeutic potential" in "preventing severe immune responses from Covid-19".

It achieved this by reducing "important biomarkers" associated with "severe Covid-19…by more than 50%".

As such, Neuro' advised the "serves as clarification" on these results. Consequently, the aim was to provide further clarity "regarding the specifics of the studies".

The explicit clarification as it were, is in reference to EmtinB's mechanism of action in the trials.

To illustrate, on Thursday the company gave a high-level overview of this, whereas, on Friday, Neuro' went into greater depths over just how EmtinB "does what it says on the tin" in this instance.

For instance, the company explained that EmtinB can "dramatically reduce" these biomarkers, which have been identified in "Covid-19 clinical studies as indicators of severe disease and poor prognosis".

Consequently, Neuroscientific reasons that by decreasing these "immune biomarkers", this indicates that EmtinB "may decrease" an inflammatory response that is significantly elevated due to Covid-19.

What did management say?

Speaking on the announcement, Neuroscientific managing director Matt Liddelow said:

These results demonstrate the significant therapeutic utility of EmtinBTM and its potential modulation of
inflammatory processes outside of the central nervous system. For the first time, our team
have demonstrated an EmtinBTM -mediated effect on adaptive immune responses as
evidenced by regulation of these inflammatory biomarkers.

Neuroscientific share price snapshot

The Neuroscientific Biopharmaceuticals share price has posted a year to date return of 34%, extending the previous 12 month's gain of 42.5%.

These results have outpaced the S&P/ASX 200 Index (ASX: XJO)'s return of around 25% over the past year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Share Gainers

4 ASX 200 shares racing ahead of the benchmark this week

ASX investors sent these four stocks soaring 12% to 18% this week. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why BHP, Coronado Global, EBR Systems, and Whitehaven Coal shares are pushing higher today

These shares are ending the week on a positive note. Let's find out why.

Read more »

a young woman looks happily at her phone in one hand with a selection of shopping bags in her other hand.
BNPL shares

Up 87% since April, why the Zip share price can keep flying higher into 2026

A leading fund manager expects more outsized gains from Zip shares ahead.

Read more »

Person pretends to types on laptop drawn in sand.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a miserly session for investors today.

Read more »

Happy coal miner.
Share Gainers

Up 75% this week, why is this ASX All Ords stock rocketing again today?

Investors are piling into this ASX 300 stock on Wednesday. But why?

Read more »

A young woman smiles as she rides a zip line high above the trees.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a bountiful session for investors this hump day.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Share Gainers

Why Coronado, DroneShield, Lovisa, and Mayne Pharma shares are racing higher today

These shares are having a good time on hump day. But why?

Read more »